Allogene Therapeutics appoints Chief Technical Officer
Allogene Therapeutics, a San Francisco clinical-stage biotech pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer, has appointed Timothy Moore as Executive Vice President, Chief Technical Officer effective April 24, 2023.
Moore succeeds Alison Moore, Ph.D., who intends to serve as a consultant to Allogene.
“The selection of Mr. Moore, the former Executive Vice President, Technical Operations of Kite Pharma responsible for the global development of two of the most commercially successful autologous CAR T manufacturing processes in the industry, reinforces the company’s mission to being the first to bring an AlloCAR T product to market,” says Allogene Therapeutics.
“As we look ahead to what could be the industry’s first regulatory submission for an allogeneic CAR T product, we are thrilled to welcome Tim Moore to our team.”
Moore has more than three decades of leadership experience in biopharmaceutical manufacturing and operations. He was Executive Vice President, Technical Operations at Kite Pharma (now a Gilead company) from 2016 to 2019, where he was responsible for the process development, manufacturing, quality and supply chain for Yescarta, the first FDA approved CAR T therapy for the treatment of non-Hodgkin lymphoma.
He and his team also developed the manufacturing process for Kite’s second FDA approved autologous CAR T therapy, Tecartus. Mr. Moore expanded biopharmaceutical operations to serve and support the US and EU as well as key partners in Asia. Most recently, he continued his effort of advancing the field of engineered cell manufacturing as Chief Operating Officer of Instil Bio, and President and Chief Operating Officer of PACT Pharma.
Prior to Kite, Moore served as the Senior Vice President, Head of Global Technical Operations – Biologics of Genentech, Inc. and as a member of the Genentech Executive Committee where he oversaw global leadership for more than 7,500 professionals across 10 internal sites and over 37 contract manufacturing organizations, as well as global manufacturing and end-to-end quality supply performance of more than 20 biological product families.
He also serves as a Board member for Cerus and BioLife Solutions. Mr. Moore received a B.S. in Chemical Engineering from Tulsa University and a M.S. in Engineering Management from Northwestern University.
